176178-88-4

Basic information

• Product Name: 4-Piperidinecarboxylicacid,1-methyl-,hydrazide(9CI)
• Synonyms: 4-Piperidinecarboxylicacid,1-methyl-,hydrazide(9CI);1-methyl-4-piperidinecarbohydrazide(SALTDATA: FREE);1-Methylpiperidine-4-carbohydrazide;1-Methyl-4-Piperidinecarbohydrazide;1-Methyl-4-piperidinecarboxylic acid, hydrazide;1-methylisonipecotohydrazide
• CAS NO: 176178-88-4
• Molecular Formula: C7H15N3O
• Molecular Weight: 157.22
• Product Categories: AMIDE
• Mol File: 176178-88-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Piperidinecarboxylicacid,1-methyl-,hydrazide(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinecarboxylicacid,1-methyl-,hydrazide(9CI)(176178-88-4)
• EPA Substance Registry System: 4-Piperidinecarboxylicacid,1-methyl-,hydrazide(9CI)(176178-88-4)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 176178-88-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
4-Piperidinecarboxylic acid, 1-methyl-, hydrazide (9CI) is used as a building block for the production of various pharmaceuticals and other biologically active compounds. Its hydrazide structure allows it to be a versatile component in the synthesis of complex organic molecules, which can be further developed into new drugs for various medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Piperidinecarboxylic acid, 1-methyl-, hydrazide (9CI) is used as a key intermediate for the synthesis of other complex organic molecules. Its reactivity in certain chemical reactions or biological processes makes it a valuable component in the development of new chemical entities with potential applications in various industries.

Upstream product

• 24252-37-7 ethyl 1-methylisonipecotate 
• 1690-75-1 1-methyl-piperidine-4-carboxylic acid methyl ester 

Downstream Products

• 1538582-61-4 C₂₆H₂₈N₄O 

Relevant articles and documents

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Synthesis of GABAA receptor agonists and evaluation of their α-subunit selectivity and orientation in the GABA binding site

Drugs used to treat various disorders target GABAA receptors. To develop α subunit selective compounds, we synthesized 5-(4-piperidyl)-3-isoxazolol (4-PIOL) derivatives. The 3-isoxazolol moiety was substituted by 1,3,5-oxadiazol-2-one, 1,3,5-oxadiazol-2-thione, and substituted 1,2,4-triazol-3-ol heterocycles with modifications to the basic piperidine substituent as well as substituents without basic nitrogen. Compounds were screened by [3H]muscimol binding and in patch-clamp experiments with heterologously expressed GABAA αiβ 3γ2 receptors (i = 1-6). The effects of 5-aminomethyl-3H-[1,3,4]oxadiazol-2-one 5d were comparable to GABA for all α subunit isoforms. 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-one 5a and 5-piperidin-4-yl-3H-[1,3,4]oxadiazol-2-thione 6a were weak agonists at α2-, α3-, and α5-containing receptors. When coapplied with GABA, they were antagonistic in α2-, α4-, and α6-containing receptors and potentiated α3-containing receptors. 6a protected GABA binding site cysteine-substitution mutants α1F64C and α1S68C from reacting with methanethiosulfonate-ethylsulfonate. 6a specifically covalently modified the α1R66C thiol, in the GABA binding site, through its oxadiazolethione sulfur. These results demonstrate the feasibility of synthesizing α subtype selective GABA mimetic drugs.